AbbVie has submitted an application to the FDA for the approval of TrenibotE — the first-in-class botulinum toxin type E. The product demonstrates a record-fast onset of action (8 hours) and a short duration of effect (2-3 weeks), which may change the approach to initial injections in patients who have previously avoided neurotoxins.

Sample informed consent form for the administration of Botox.

Article under preparation This article is currently available only in Russian. You can switch the language in the top language bar to view the Russian version, or check back soon — the English translation will be available shortly.  

On the correction of a gummy smile, mimic wrinkles, and age-related changes in the lower third of the face and neck, as well as combined techniques for the use of botulinum toxin type A.

On the correction of mimic wrinkles and age-related changes in the upper third of the face (forehead, glabella, eyebrows, eyes, nose) using botulinum toxin type A.

Allergan Announces Results of Higher Dose BOTOX® Cosmetic (onabotulinumtoxin A) for the Treatment of Moderate to Severe Glabellar Lines.

Who chooses botulinum toxin type A — Xeomin? Who can it be recommended for? Features of correction in different areas of the face and neck. Injection technique guidance and possible adverse effects.

Modern aesthetic medicine offers two identical products for eliminating expression lines — Botox and Dysport. But how do they differ? And which one should you choose?

Many people have noticed that lately the effect of Botox has become shorter. Previously, the results lasted about six months, but now only around three. Is it tolerance? Are cosmetologists diluting the product more? Has the composition of the drug changed?

Today, the professional market offers an entire family of botulinum toxin–containing drugs, but they are not “twins” and have different safety and efficacy profiles, as well as differences related to production, composition, and application protocols.